JP2022527173A5 - - Google Patents
Info
- Publication number
- JP2022527173A5 JP2022527173A5 JP2021557602A JP2021557602A JP2022527173A5 JP 2022527173 A5 JP2022527173 A5 JP 2022527173A5 JP 2021557602 A JP2021557602 A JP 2021557602A JP 2021557602 A JP2021557602 A JP 2021557602A JP 2022527173 A5 JP2022527173 A5 JP 2022527173A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- seq
- variable region
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825955P | 2019-03-29 | 2019-03-29 | |
| US62/825,955 | 2019-03-29 | ||
| US201962859843P | 2019-06-11 | 2019-06-11 | |
| US62/859,843 | 2019-06-11 | ||
| US201962896758P | 2019-09-06 | 2019-09-06 | |
| US62/896,758 | 2019-09-06 | ||
| PCT/US2020/024432 WO2020205331A1 (en) | 2019-03-29 | 2020-03-24 | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527173A JP2022527173A (ja) | 2022-05-31 |
| JP2022527173A5 true JP2022527173A5 (cg-RX-API-DMAC7.html) | 2022-06-29 |
Family
ID=72667032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557602A Pending JP2022527173A (ja) | 2019-03-29 | 2020-03-24 | ヒト化抗クローディン18.2キメラ抗原受容体及びその使用 |
Country Status (12)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7840511B2 (ja) | 2019-02-01 | 2026-04-06 | 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 | 抗クローディン18抗体及びそれらの使用の方法 |
| WO2022122709A1 (en) * | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| CN115073606B (zh) * | 2021-03-10 | 2025-05-02 | 上海莱馥医疗科技有限公司 | 一种靶向表达cldn 18.2的细胞的人源化嵌合抗原受体 |
| CN113354739B (zh) * | 2021-01-11 | 2022-08-23 | 上海莱馥医疗科技有限公司 | 一种靶向表达Claudin18.2细胞的嵌合抗原受体及其应用 |
| KR20240044467A (ko) | 2021-08-09 | 2024-04-04 | 하버 바이오메드 (상하이) 컴퍼니 리미티드 | Cldn18.2-표적화 항체, 이중특이적 항체, 및 이들의 용도 |
| AU2023276514A1 (en) * | 2022-05-27 | 2024-12-05 | Shenzhen Immunofoco Biotechnology Co., Ltd. | Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof |
| KR20250087608A (ko) * | 2022-10-10 | 2025-06-16 | 메디뮨 엘엘씨 | 클라우딘 18.2를 표적화하는 키메라 항원 수용체로 암을 치료하는 조성물 및 방법 |
| WO2025255276A1 (en) * | 2024-06-04 | 2025-12-11 | Fred Hutchinson Cancer Center | Anti-whitlow linker binding domains and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| IL282953B2 (en) * | 2012-11-13 | 2026-02-01 | Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh | Agents for the treatment of claudin-expressing cancers |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| WO2018006882A1 (zh) * | 2016-07-08 | 2018-01-11 | 科济生物医药(上海)有限公司 | 抗密蛋白18a2的抗体及其应用 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| MX2020009326A (es) * | 2018-03-08 | 2020-10-08 | Phanes Therapeutics Inc | Anticuerpos anti-claudina 18.2 y usos de los mismos. |
-
2020
- 2020-03-24 WO PCT/US2020/024432 patent/WO2020205331A1/en not_active Ceased
- 2020-03-24 AU AU2020253792A patent/AU2020253792A1/en not_active Abandoned
- 2020-03-24 CN CN202080026574.XA patent/CN113784980B/zh active Active
- 2020-03-24 JP JP2021557602A patent/JP2022527173A/ja active Pending
- 2020-03-24 MX MX2021011887A patent/MX2021011887A/es unknown
- 2020-03-24 CA CA3132201A patent/CA3132201A1/en active Pending
- 2020-03-24 US US17/593,066 patent/US20220184126A1/en not_active Abandoned
- 2020-03-24 EP EP20784482.0A patent/EP3947468A1/en not_active Withdrawn
- 2020-03-24 KR KR1020217034225A patent/KR20210144792A/ko not_active Withdrawn
- 2020-03-24 BR BR112021016673-4A patent/BR112021016673A2/pt not_active Application Discontinuation
- 2020-03-24 SG SG11202109052Y patent/SG11202109052YA/en unknown
-
2021
- 2021-09-26 IL IL286696A patent/IL286696A/en unknown